semaglutide + cagrilintide Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes Cagrilintide & GLP-1 S |

IV NAD therapies are not FDA-approved , have no standardized dosing, and may cause nausea, flushing, anxiety, or tachycardia

PubMed Gastric pentadecapeptide BPC 157 and its role in accelerating musculoskeletal soft tissue healing Supports cautious tissue-repair context without presenting BPC-157 as an approved therapy

(1988) Sleep-inducing effect of low doses of DSIP in rats

If you are very B12 deficient you will notice an increase in energy and a reduction in symptoms of tingling, numbness, or twitching/zaps within 24 hours

However, another study on the effects of BPC-157 in treating urinary incontinence in mice indicated equal measures of effectiveness in both oral and intraperitoneal administration